8-K: Microbot Medical Faces Nasdaq Delisting Threat After Share Price Slips Below $1

Microbot Medical Inc. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing the company at risk of delisting.

Summary

• Microbot Medical Inc. has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement for continued listing.
• The company's stock price has been below $1.00 for 30 consecutive business days, from August 26, 2024 to October 7, 2024.
• Microbot Medical has until April 7, 2025, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If the company fails to meet this requirement, it may be granted an additional 180 days if it meets other listing requirements and provides notice of its intention to cure the deficiency, potentially through a reverse stock split.
• Failure to regain compliance could lead to delisting from the Nasdaq Capital Market, though the company can appeal such a decision.
• The company intends to hold its annual meeting of stockholders on or about December 17, 2024.
• The deadline for shareholder proposals and director nominations for the annual meeting is October 25, 2024.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting notice) and uncertainty about the company's ability to regain compliance, leading to a low sentiment score.

Positives

• Microbot Medical has been given a 180-day period to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be eligible for an additional 180 days to regain compliance if it meets certain conditions.
• The company has the option to appeal a delisting decision.

Negatives

• The company's stock price has been below $1.00 for 30 consecutive business days, triggering a delisting warning from Nasdaq.
• There is no guarantee that the company will be able to regain compliance with the minimum bid price requirement.
• The company faces the risk of being delisted from the Nasdaq Capital Market.

Risks

• The company faces the risk of delisting from the Nasdaq Capital Market if it cannot regain compliance with the minimum bid price requirement.
• There is no assurance that the company will be able to regain compliance or that an appeal of a delisting decision would be successful.
• The company may need to implement a reverse stock split to regain compliance, which could negatively impact shareholders.

Future Outlook

The company is focused on regaining compliance with Nasdaq listing requirements, potentially through a reverse stock split, and is preparing for its annual shareholder meeting.

Management Comments

• The company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, but there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.

Industry Context

This announcement highlights the challenges faced by smaller companies in maintaining their stock price above the minimum threshold required for listing on major exchanges like Nasdaq. It is not uncommon for companies in the biotech and medical device sectors to experience volatility in their stock price, which can lead to such compliance issues.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining their stock price above the minimum bid price required by exchanges like Nasdaq.
• Companies like Avinger and Titan Medical have also faced delisting risks due to low stock prices.
• A reverse stock split is a common strategy used by companies in this situation to increase their stock price and regain compliance.
• The 180-day compliance period is a standard procedure for companies facing delisting due to minimum bid price deficiencies.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• The company must regain compliance with the minimum bid price requirement by April 7, 2025.
• The company may need to implement a reverse stock split to increase its stock price.
• The company will hold its annual meeting of stockholders on or about December 17, 2024.
• The company will need to respond to the Nasdaq deficiency letter and potentially appeal any delisting decision.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, stock price, reverse stock split, shareholder meeting, director nominations